تحلیل اختیاری محصول
با اجازه شما، از تحلیلهای محدود و حریمخصوصیمحور استفاده میکنیم تا مسیرهای پژوهشی مؤثر را بشناسیم. از ردیاب تبلیغاتی یا بازپخش نشست استفاده نمیکنیم. این انتخاب را میتوانید در تنظیمات تغییر دهید. بخوانید سیاست حفظ حریم خصوصی.
Elevance Health Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $94.1B | |
|---|---|---|
| Revenue (ttm) | 201.8B | |
| Net income (ttm) | 5.1B | |
| EPS (ttm) | $23.4 | |
| Shares out | 216.1M | |
| P/E (trailing) | 17.6x | |
| P/E (forward) | 13.7x | |
| Dividend | $6.88 (1.67%) | |
| Volume | 858,930 | |
| Beta | 0.71 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $138.64B | $156.60B | $171.34B | $177.01B | $199.13B | +9.5% |
| Gross profit | $35.99B | $39.95B | $47.01B | $49.24B | $50.90B | +9.1% |
| Operating income | $7.56B | $8.28B | $8.50B | $7.86B | $7.20B | -1.2% |
| Net income | $6.16B | $5.89B | $5.99B | $5.98B | $5.66B | -2.1% |
| EPS (diluted) | $24.95 | $24.28 | $25.22 | $25.68 | $25.21 | +0.3% |
| EBITDA | $10.03B | $10.13B | $10.49B | $10.48B | $9.66B | -0.9% |
| R&D | — | — | — | — | — | — |
| SG&A | $15.92B | $17.70B | $20.09B | $20.03B | $20.98B | +7.2% |
Recent company headlines from major financial publishers.
Medicare Advantage underwriting margins accelerate toward management target ranges ahead of schedule, supported by Star Rating recoveries and favorable claims development. Carelon secures major third-party external selling wins, expanding service operating margins substantially. Consolidated operating margins expand meaningfully, driving accelerated annual adjusted earnings growth with valuation multiple expansion.
Elevance executes disciplined commercial pricing resets matching low-double-digit cost inflation while state Medicaid rate adjustments gradually restore underwriting margins. Carelon continues steady 5% revenue expansion with 5.3% pharmacy operating margins. Consolidated operating margins normalize from 3.6% in 2025 to 4.2% by 2030, supporting our fair value midpoint of $474.64 (+9.33% implied upside).
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 7.4% | $513 | $525 | $538 | $553 | $570 |
| 7.9% | $483 | $493 | $504 | $516 | $529 |
| 8.4% | $458 | $466 | $475 | $484 | $495 |
| 8.9% | $436 | $442 | $450 | $458 | $466 |
| 9.4% | $416 | $422 | $428 | $435 | $442 |
Upcoming earnings date and setup when available.
رتبهای که نسخهٔ پژوهشی منتشرشدهٔ هر ماه داشت. رتبه قیمت در تاریخ تحلیل را با ارزش منصفانه مقایسه میکند و سابقهای از درستی یا نادرستی ارزیابی نیست.
| سال | دی | بهمن | اسفند | فروردین | اردیبهشت | خرداد | تیر | مرداد | شهریور | مهر | آبان | آذر |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
